基于指南的ST段抬高型心肌梗死后长期二级预防治疗与风险因素控制最新进展

doi:10.12114/j.issn.1007-9572.2019.00.029

摘要/Abstract

摘要： ST段抬高型心肌梗死（STEMI）患者急性期的关键治疗是快速再灌注，成功再灌注后所有患者处于心血管事件再发极高危状态，需要依据国内外最新进展推荐进行二级预防治疗和风险因素控制。STEMI患者的长期管理治疗包括：心肌缺血的无创性评价，左心室功能和心源性猝死评价，戒烟，以运动为基础的心脏康复，饮食和体质量控制，血压控制，血糖管理，降脂治疗，长期抗栓治疗，β-受体阻滞剂，血管紧张素转换酶抑制剂（ACEI）和血管紧张素Ⅱ受体拮抗剂（ARB），盐皮质激素受体拮抗剂（MRA），改善循证治疗依从性，以及促进治疗协调性的医疗保健体系。

关键词: ST段抬高型心肌梗死, 风险评价, 二级预防, 药物疗法, 心脏康复

Abstract: In patients with ST-segment elevation myocardial infarction（STEMI），the key management is fast reperfusion therapy in the acute setting；after successful reperfusion，all patients are considered to be at sufficiently high risk to merit interventions for secondary prevention and risk factors based on the latest domestic and foreign evidence.Long-term management for STEMI includes noninvasive testing for ischemia，assessment of left ventricular function and risk for sudden cardiac death （SCD），cessation of smoking，exercise-based cardiac rehabilitation，diet advice and weight control，optimal blood pressure control，hyperglycemic management，lipid-lowering therapy，long-term antithrombotic therapy，beta-blockers，angiotensin-converting enzyme inhibitors（ACEI） and angiotensin Ⅱ receptor blockers（ARB），mineralocorticoid receptor antagonist （MRA） therapy，improvement of evidence-based treatment compliance，and system of care to promote care coordination.

Key words: ST-segment elevation myocardial infarction, Risk assessment, Secondary prevention, Drug therapy, Cardiac rehabilitation

梁峰,胡大一,方全,等. 基于指南的ST段抬高型心肌梗死后长期二级预防治疗与风险因素控制最新进展[J]. 中国全科医学, 2019, 22(8): 888-900. DOI: 10.12114/j.issn.1007-9572.2019.00.029.
LIANG Feng,HU Dayi,FANG Quan, et al. Recent Advances on Long-term Secondary Prevention and Risk Factors Control for ST-segment Elevation Myocardial Infarction Based on the Latest Evidence[J]. Chinese General Practice, 2019, 22(8): 888-900. DOI: 10.12114/j.issn.1007-9572.2019.00.029.

参考文献

［1］IBANEZ B，JAMES S，AGEWALL S，et al．2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation：the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology（ESC）［J］．Eur Heart J，2018，39（2）：119-177．DOI：10.1093/eurheartj/ehx393.
［2］American College of Emergency Physicians，Society for Cardiovascular Angiography and Interventions.2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction：a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines［J］．J Am Coll Cardiol，2013，61（4）：e78-140．DOI：10.1016/j.jacc.2012.11.019.
［3］PIEPOLI M F，HOES A W，AGEWALL S，et al．2016 European guidelines on cardiovascular disease prevention in clinical practice：the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice（constituted by representatives of 10 societies and by invited experts）Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation（EACPR）［J］．Eur Heart J，2016，37（29）：2315-2381．DOI：10.1093/eurheartj/ehw106.
［4］WIJEYSUNDERA H C，VIJAYARAGHAVAN R，NALLAMOTHU B K，et al．Rescue angioplasty or repeat fibrinolysis after failed fibrinolytic therapy for ST-segment myocardial infarction：a meta-analysis of randomized trials［J］．J Am Coll Cardiol，2007，49（4）：422-430．DOI：10.1016/j.jacc.2006.09.033.
［5］FOX K A，DABBOUS O H，GOLDBERG R J，et al．Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome：prospective multinational observational study （GRACE）［J］．BMJ，2006，333（7578）：1091．DOI：10.1136/bmj.38985.646481.55.
［6］FOX K A，FITZGERALD G，PUYMIRAT E，et al．Should patients with acute coronary disease be stratified for management according to their risk？Derivation，external validation and outcomes using the updated GRACE risk score［J］．BMJ Open，2014，4（2）：e004425．DOI：10.1136/bmjopen-2013-004425.
［7］SMITH S C Jr，BENJAMIN E J，BONOW R O，et al．AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease：2011 update：a guideline from the American Heart Association and American College of Cardiology Foundation［J］．J Am Coll Cardiol，2011，58（23）：2432-2446．DOI：10.1016/j.jacc.2011.10.824.
［8］VILLELLA A，MAGGIONI A P，VILLELLA M，et al．Prognostic significance of maximal exercise testing after myocardial infarction treated with thrombolytic agents：the GISSI-2 data-base.Gruppo Italiano per lo Studio della Sopravvivenza Nell'Infarto［J］．Lancet，1995，346（8974）：523-529.
［9］WINDECKER S，KOLH P，ALFONSO F，et al．2014 ESC/EACTS guidelines on myocardial revascularization：the Task Force on Myocardial Revascularization of the European Society of Cardiology（ESC） and the European Association for Cardio-Thoracic Surgery（EACTS）．Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions（EAPCI）［J］．Eur Heart J，2014，35（37）：2541-2619．DOI：10.1093/eurheartj/ehu278.
［10］BULLUCK H，WHITE S K，FROHLICH G M，et al．Quantifying the area at risk in reperfused ST-segment-elevation myocardial infarction patients using hybrid cardiac positron emission tomography-magnetic resonance imaging［J］．Circ Cardiovasc Imaging，2016，9（3）：e003900．DOI：10.1161/CIRCIMAGING.115.003900.
［11］STEINBECK G，ANDRESEN D，SEIDL K，et al．Defibrillator implantation early after myocardial infarction［J］．N Engl J Med，2009，361（15）：1427-1436．DOI：10.1056/NEJMoa0901889.
［12］OLGIN J E，PLETCHER M J，VITTINGHOFF E，et al．Wearable cardioverter-defibrillator after myocardial infarction［J］．N Engl J Med，2018，379（13）：1205-1215．DOI：10.1056/NEJMoa1800781.
［13］PRIORI S G，BLOMSTROM-LUNDQVIST C，MAZZANTI A，
et al．2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death：the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology（ESC）．Endorsed by：association for European Paediatric and Congenital Cardiology（AEPC）［J］．Eur Heart J，2015，36（41）：2793-2867．DOI：10.1093/eurheartj/ehv316.
［14］BARDY G H，LEE K L，MARK D B，et al．Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure［J］．N Engl J Med，2005，352（3）：225-237.
［15］BRIGNOLE M，MOYA A，DE LANGE F J，et al．2018 ESC guidelines for the diagnosis and management of syncope［J］．Eur Heart J，2018，39（21）：1883-1948．DOI：10.1093/eurheartj/ehy037.
［16］COLEMAN E A，MAHONEY E，PARRY C.Assessing the quality of preparation for posthospital care from the patient's perspective：the care transitions measure［J］．Med Care，2005，43（3）：246-255.
［17］WILSON K，GIBSON N，WILLAN A，et al．Effect of smoking cessation on mortality after myocardial infarction：meta-analysis of cohort studies［J］．Arch Intern Med，2000，160（7）：939-944.
［18］CRITCHLEY J A，CAPEWELL S.Mortality risk reduction associated with smoking cessation in patients with coronary heart disease：a systematic review［J］．JAMA，2003，290（1）：86-97.
［19］DAWOOD N，VACCARINO V，REID K J，et al．Predictors of smoking cessation after a myocardial infarction：the role of institutional smoking cessation programs in improving success［J］．Arch Intern Med，2008，168（18）：1961-1967．DOI：10.1001/archinte.168.18.1961.
［20］BALADY G J，WILLIAMS M A，ADES P A，et al．Core components of cardiac rehabilitation/secondary prevention programs：2007 update：a scientific statement from the American Heart Association Exercise，Cardiac Rehabilitation，and Prevention Committee，the Council on Clinical Cardiology；the Councils on Cardiovascular Nursing，Epidemiology and Prevention，and Nutrition，Physical Activity，and Metabolism；and the American Association of Cardiovascular and Pulmonary Rehabilitation［J］．Circulation，2007，115（20）：2675-2682.
［21］SUAYA J A，STASON W B，ADES P A，et al．Cardiac rehabilitation and survival in older coronary patients［J］．J Am Coll Cardiol，2009，54（1）：25-33.
［22］TAYLOR R S，BROWN A，EBRAHIM S，et al．Exercise-based rehabilitation for patients with coronary heart disease：systematic review and meta-analysis of randomized controlled trials［J］．Am J Med，2004，116（10）：682-692．DOI：10.1016/j.amjmed.2004.01.009.
［23］THOMAS R J，KING M，LUI K，et al．AACVPR/ACCF/AHA 2010 update：performance measures on cardiac rehabilitation for referral to cardiac rehabilitation/secondary prevention services［J］．Circulation，2010，122（13）：1342-1350.
［24］ANDERSON L，OLDRIDGE N，THOMPSON D R，et al．Exercise-based cardiac rehabilitation for coronary heart disease：cochrane systematic review and meta-analysis［J］．J Am Coll Cardiol，2016，67（1）：1-12．DOI：10.1016/j.jacc.2015.10.044.
［25］中华医学会心血管病学分会，中国康复医学会心血管病专业委员会，中国老年学学会心脑血管病专业委员会.冠心病康复与二级预防中国专家共识［J］．中华心血管病杂志，2013，41（4）：267-275．DOI：10.3760/cma.j.issn.0253-3758.2013.04.003.
［26］中华医学会心血管病学分会预防学组，中国康复医学会心血管病专业委员会.冠心病患者运动治疗中国专家共识［J］．中华心血管病杂志，2015，43（7）：575-588．DOI：10.3760/cma.j.issn.0253-3758.2015.07.004.
［27］SMITH D，TOFF W，JOY M，et al．Fitness to fly for passengers with cardiovascular disease［J］．Heart，2010，96（Suppl 2）：ii1-16．DOI：10.1136/hrt.2010.203091.
［28］WRIGHT J T Jr，WILLIAMSON J D，WHELTON P K，et al．A randomized trial of intensive versus standard blood-pressure control［J］．N Engl J Med，2015，373（22）：2103-2116.
［29］WHELTON P K，CAREY R M，ARONOW W S，et al．2017 ACC/AHA/AAPA/ABC/ACPM/AGS /APhA/ASH/ASPC/NMA/PCNA guideline for the prevention，detection，evaluation，and management of high blood pressure in adults：a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines［J］．J Am Coll Cardiol，2018，71（19）：e127-248.
［30］American Diabetes Association.9.Cardiovascular disease and risk management：standards of medical care in diabetes-2018［J］．Diabetes Care，2018，41（Suppl 1）：S86-104．DOI：10.2337/dc18-S009.
［31］Cholesterol Treatment Trialists' （CTT） Collaboration，BAIGENT C，BLACKWELL L，et al．Efficacy and safety of more intensive lowering of LDL cholesterol：a meta-analysis of data from 170，000 participants in 26 randomised trials［J］．Lancet，2010，376（9753）：1670-1681．DOI：10.1016/S0140-6736（10）61350-5.
［32］CANNON C P，BLAZING M A，GIUGLIANO R P，et al．
Ezetimibe added to statin therapy after acute coronary syndromes［J］．N Engl J Med，2015，372（25）：2387-2397．DOI：10.1056/NEJMoa1410489.
［33］BOHULA E A，MORROW D A，GIUGLIANO R P，et al．Atherothrombotic risk stratification and ezetimibe for secondary prevention［J］．J Am Coll Cardiol，2017，69（8）：911-921．DOI：10.1016/j.jacc.2016.11.070.
［34］SABATINE M S，GIUGLIANO R P，KEECH A C，et al．Evolocumab and clinical outcomes in patients with cardiovascular disease［J］．N Engl J Med，2017，376（18）：1713-1722．DOI：10.1056/NEJMoa1615664.
［35］POCOCK S J，COLLIER T J.Critical appraisal of the 2018 ACC scientific sessions late-breaking trials from a statistician's perspective［J］．J Am Coll Cardiol，2018，71（25）：2957-2969．DOI：10.1016/j.jacc.2018.04.015.
［36］CATAPANO A L，GRAHAM I，DE BACKER G，et al．2016 ESC/EAS guidelines for the management of dyslipidaemias［J］．Eur Heart J，2016，37（39）：2999-3058．DOI：10.1093/eurheartj/ehw272.
［37］GRUNDY S M，STONE N J，BAILEY A L，et al．2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol：a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines［J］．J Am Coll Cardiol，2018，8.pii：S0735-1097（18）39034-X．DOI：10.1016/j.jacc.2018.11.003.
［38］胡大一.穿中国鞋走中国路圆中国健康梦［J］．中华心血管病杂志，2015，43（1）：1-2．DOI：10.3760/cma.j.issn.0253-3758.2015.01.001.
［39］中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南（2016年修订版）［J］．中国循环杂志，2016，31（10）：937-950．DOI：10.3969/j.issn.1000-3614.2016.10.001.
［40］BHATT D L，STEG P G，MILLER M，et al．Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia［J］．N Engl J Med，2018．［Epub ahead of print］．DOI：10.1056/NEJMoa1812792．
［41］CURRENT-OASIS 7 Investigators，MEHTA S R，BASSAND J P，et al．Dose comparisons of clopidogrel and aspirin in acute coronary syndromes［J］．N Engl J Med，2010，363（10）：930-942．DOI：10.1056/NEJMoa0909475.
［42］VALGIMIGLI M，BUENO H，BYRNE R A，et al．2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS：the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology（ESC） and of the European Association for Cardio-Thoracic Surgery（EACTS）［J］．Eur Heart J，2018，39（3）：213-260．DOI：10.1093/eurheartj/ehx419.
［43］BERWANGER O，NICOLAU J C，CARVALHO A C，et al．Ticagrelor vs clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction：a randomized clinical trial［J］．JAMA Cardiol，2018，3（5）：391-399．DOI：10.1001/jamacardio.2018.0612.
［44］VALGIMIGLI M，CAMPO G，MONTI M，et al．Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting：a randomized multicenter trial［J］．Circulation，2012，125（16）：2015-2026．DOI：10.1161/CIRCULATIONAHA.111.071589.
［45］BONACA M P，BHATT D L，COHEN M，et al．Long-term use of ticagrelor in patients with prior myocardial infarction［J］．N Engl J Med，2015，372（19）：1791-1800.
［46］MEGA J L，BRAUNWALD E，WIVIOTT S D，et al．Rivaroxaban in patients with a recent acute coronary syndrome［J］．N Engl J Med，2012，366（1）：9-19．DOI：10.1056/NEJMoa1112277.
［47］GIBSON C M，MEHRAN R，BODE C，et al．Prevention of bleeding in patients with atrial fibrillation undergoing PCI［J］．N Engl J Med，2016，375（25）：2423-2434．DOI：10.1056/NEJMoa1611594.
［48］MORROW D A，BRAUNWALD E，BONACA M P，et al．Vorapaxar in the secondary prevention of atherothrombotic events［J］．N Engl J Med，2012，366（15）：1404-1413．DOI：10.1056/NEJMoa1200933.
［49］CANNON C P，BHATT D L，OLDGREN J，et al．Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation［J］．N Engl J Med，2017，377（16）：1513-1524．DOI：10.1056/NEJMoa1708454.
［50］IBANEZ B，MACAYA C，SáNCHEZ-BRUNETE V，et al．Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention：the effect of metoprolol in cardioprotection during an acute myocardial infarction（METOCARD-CNIC） trial［J］．Circulation，2013，128（14）：1495-1503．DOI：10.1161/CIRCULATIONAHA.113.003653.
［51］ROOLVINK V，IBANEZ B，OTTERVANGER J P，et al．Early intravenous beta-blockers in patients with ST-segment elevation myocardial infarction before primary percutaneous coronary intervention［J］．J Am Coll Cardiol，2016，67（23）：2705-2715.
［52］BUGIARDINI R，CENKO E，RICCI B，et al．Comparison of early versus delayed oral beta blockers in acute coronary syndromes and effect on outcomes［J］．Am J Cardiol，2016，117（5）：760-767．DOI：10.1016/j.amjcard.2015.11.059.
［53］GOLDBERGER J J，BONOW R O，CUFFE M，et al．Effect of beta-blocker dose on survival after acute myocardial infarction［J］．J Am Coll Cardiol，2015，66（13）：1431-1441．DOI：10.1016/j.jacc.2015.07.047.
［54］ANDERSSON C，SHILANE D，GO A S，et al．Beta-blocker therapy and cardiac events among patients with newly diagnosed coronary heart disease［J］．J Am Coll Cardiol，2014，64（3）：247-252．DOI：10.1016/j.jacc.2014.04.042.
［55］BANGALORE S，STEG G，DEEDWANIA P，et al．Beta-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease［J］．JAMA，2012，308（13）：1340-1349．DOI：10.1001/jama.2012.12559.
［56］ANDREASEN C，ANDERSSON C.Current use of beta-blockers in patients with coronary artery disease［J］．Trends Cardiovasc Med，2018，28（6）：382-389．DOI：10.1016/j.tcm.2017.12.014.
［57］ISIS-4 （Fourth International Study of Infarct Survival） Collaborative Group.ISIS-4：a randomised factorial trial assessing early oral captopril，oral mononitrate，and intravenous magnesium sulphate in 58，050 patients with suspected acute myocardial infarction［J］．Lancet，1995，345（8951）：669-685.
［58］ACE Inhibitor Myocardial Infarction Collaborative Group.Indications for ACE inhibitors in the early treatment of acute myocardial infarction：systematic overview of individual data from 100，000 patients in randomized trials［J］．Circulation，1998，97（22）：2202-2212.
［59］PFEFFER M A，MCMURRAY J J，VELAZQUEZ E J，et al．Valsartan，captopril，or both in myocardial infarction complicated by heart failure，left ventricular dysfunction，or both［J］．N Engl J Med，2003，349（20）：1893-1906.
［60］PITT B，REMME W，ZANNAD F，et al．Eplerenone，a selective aldosterone blocker，in patients with left ventricular dysfunction after myocardial infarction［J］．N Engl J Med，2003，348（14）：1309-1321.
［61］MONTALESCOT G，PITT B，LOPEZ DE SA E，et al．Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure：the randomized double-blind reminder study［J］．Eur Heart J，2014，35（34）：2295-2302.
［62］BEYGUI F，CAYLA G，ROULE V，et al．Early aldosterone blockade in acute myocardial infarction：the ALBATROSS randomized clinical trial［J］．J Am Coll Cardiol，2016，67（16）：1917-1927．DOI：10.1016/j.jacc.2016.02.033.
［63］HELD P H，YUSUF S，FURBERG C D.Calcium channel blockers in acute myocardial infarction and unstable angina：an overview［J］．BMJ，1989，299（6709）：1187-1192.
［64］Effect of verapamil on mortality and major events after acute myocardial infarction （the Danish Verapamil Infarction Trial Ⅱ—DAVIT Ⅱ）［J］．Am J Cardiol，1990，66（10）：779-785.
［65］NADERI S H，BESTWICK J P，WALD D S.Adherence to drugs that prevent cardiovascular disease：meta-analysis on 376，162 patients［J］．Am J Med，2012，125（9）：882–887.e1．DOI：10.1016/j.amjmed.2011.12.013.
［66］CASTELLANO J M，SANZ G，PENALVO J L，et al．A polypill strategy to improve adherence：results from the FOCUS project［J］．J Am Coll Cardiol，2014，64（20）：2071-2082．DOI：10.1016/j.jacc.2014.08.021.
［67］SNOW V，BECK D，BUDNITZ T，et al．Transitions of care consensus policy statement American College of Physicians-Society of General Internal Medicine-Society of Hospital Medicine-American Geriatrics Society-American College of Emergency Physicians-Society of Academic Emergency Medicine［J］．J Gen Intern Med，2009，24（8）：971-976．DOI：10.1007/s11606-009-0969-x.

[1]	苗广瑞, 庞硕, 周远航, 段铭烜, 白琳鹏, 张擎阳, 赵晓燕, 董建增. 早期液体平衡和乳酸清除率对体外膜肺氧合辅助治疗急性心肌梗死合并心源性休克患者的短期预后价值研究[J]. 中国全科医学, 2023, 26(27): 3397-3402.
[2]	刘晶涛, 苏荷, 秦小金, 兰云霞, 张金枝. 冠心病患者心脏康复相关指南的系统评价[J]. 中国全科医学, 2023, 26(19): 2323-2331.
[3]	陈轶琳, 林平, 韩永奎, 王旖旎. 经皮冠状动脉介入治疗患者Ⅰ期心脏康复依从性及影响因素模型的构建研究[J]. 中国全科医学, 2023, 26(18): 2209-2216.
[4]	王秋琴, 章雨桐, 徐语晨, 柏亚妹, 陈华, 姜荣荣, 严姝霞, 王庆, 徐桂华, 谢颖, 乔春, 杨娟. 刮痧联合药物治疗原发性帕金森病的短期临床疗效研究[J]. 中国全科医学, 2023, 26(17): 2155-2161.
[5]	中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南（2022）[J]. 中国全科医学, 2023, 26(14): 1671-1691.
[6]	宋平安, 陈晓亮, 姚远, 高瑾, 杨洋, 崔洪春, 张毅. 程序性死亡蛋白-1抑制剂单药治疗老年晚期非小细胞肺癌患者的疗效及安全性研究[J]. 中国全科医学, 2023, 26(02): 241-247.
[7]	唐宇, 谭惠文, 李建薇, 余叶蓉. 国际垂体协会《库欣病的诊断和管理共识（更新版）》解读——药物篇[J]. 中国全科医学, 2022, 25(36): 4483-4490.
[8]	贾思琦, 王迪, 鲁燕, 贾永平. 高强度间歇训练对心肌梗死大鼠心脏结构和功能的影响[J]. 中国全科医学, 2022, 25(33): 4159-4167.
[9]	张鹏翔, 曾霖, 孟璐, 黄倩, 王高祥, 刘德亮. 治疗2型糖尿病新靶点药物研究新进展[J]. 中国全科医学, 2022, 25(20): 2551-2557.
[10]	李玲, 张会娟. 作用于垂体治疗库欣病的药物研究进展[J]. 中国全科医学, 2022, 25(14): 1789-1794.
[11]	陈晓奉, 王蒙, 李忠玉, 李佳佳. Venetoclax联合化疗治疗复发/难治性急性髓系白血病的临床研究[J]. 中国全科医学, 2022, 25(08): 957-962.
[12]	郝潇, 赵美, 李树仁. STEMI直接PCI术后合并超常射血分数患者LVEF临界值及其可能机制初探[J]. 中国全科医学, 2022, 25(05): 547-553.
[13]	杨荣军, 史钰芳, 王庆海. 慢性心力衰竭与抑郁症共同发病机制及药物治疗的研究进展[J]. 中国全科医学, 2022, 25(05): 625-630.
[14]	李正欢, 张晓云, 陈杨, 宋雪利, 刘昕. 基于2021年GOLD《COPD诊断、治疗与预防全球策略》解析慢性阻塞性肺疾病稳定期非药物管理策略[J]. 中国全科医学, 2022, 25(02): 131-138.
[15]	杜亚格，张丽萍，刘婕，窦昊颖，张春梅. 虐待老年人三级预防的研究进展[J]. 中国全科医学, 2021, 24(9): 1131-1135.